Role of immune activation in progression to AIDS

Netanya S. Utay, Peter W. Hunt

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose of review The purpose is to review recent insights into the impact of HIV-associated immune activation on AIDS and non-AIDS morbidity and mortality. Recent findings Immune activation has long been recognized as an important consequence of untreated HIV infection and predictor of AIDS progression, which declines but fails to normalize during suppressive antiretroviral therapy, and continues to predict disease in this setting. Thus, a major research agenda is to develop novel therapies to reduce persistent immune activation in treated HIV infection. Yet, the optimal targets for interventions remain unclear. Both the specific root causes of immune activation and the many interconnected pathways of immune activation that are most likely to drive disease risk in HIV-infected individuals remain incompletely characterized, but recent studies have shed new light on these topics. Summary In the context of this review, we will summarize recent evidence helping to elucidate the immunologic pathways that appear most strongly predictive of infectious and noninfectious morbidity. We will also highlight the likelihood that not all root drivers of immune activation - and the discrete immunologic pathways to which they give rise - are likely to produce the same disease manifestations and/or be equally attenuated by early antiretroviral therapy initiation.

Original languageEnglish (US)
Pages (from-to)131-137
Number of pages7
JournalCurrent Opinion in HIV and AIDS
Volume11
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Acquired Immunodeficiency Syndrome
HIV Infections
HIV
Morbidity
Secondary Prevention
Mortality
Therapeutics
Research

Keywords

  • AIDS
  • HIV infection
  • immune activation
  • monocyte activation
  • non-AIDS events

ASJC Scopus subject areas

  • Hematology
  • Oncology(nursing)
  • Immunology
  • Infectious Diseases
  • Virology
  • Oncology

Cite this

Role of immune activation in progression to AIDS. / Utay, Netanya S.; Hunt, Peter W.

In: Current Opinion in HIV and AIDS, Vol. 11, No. 2, 01.03.2016, p. 131-137.

Research output: Contribution to journalArticle

Utay, Netanya S. ; Hunt, Peter W. / Role of immune activation in progression to AIDS. In: Current Opinion in HIV and AIDS. 2016 ; Vol. 11, No. 2. pp. 131-137.
@article{11dd1ee35551497492f02db768f77c0f,
title = "Role of immune activation in progression to AIDS",
abstract = "Purpose of review The purpose is to review recent insights into the impact of HIV-associated immune activation on AIDS and non-AIDS morbidity and mortality. Recent findings Immune activation has long been recognized as an important consequence of untreated HIV infection and predictor of AIDS progression, which declines but fails to normalize during suppressive antiretroviral therapy, and continues to predict disease in this setting. Thus, a major research agenda is to develop novel therapies to reduce persistent immune activation in treated HIV infection. Yet, the optimal targets for interventions remain unclear. Both the specific root causes of immune activation and the many interconnected pathways of immune activation that are most likely to drive disease risk in HIV-infected individuals remain incompletely characterized, but recent studies have shed new light on these topics. Summary In the context of this review, we will summarize recent evidence helping to elucidate the immunologic pathways that appear most strongly predictive of infectious and noninfectious morbidity. We will also highlight the likelihood that not all root drivers of immune activation - and the discrete immunologic pathways to which they give rise - are likely to produce the same disease manifestations and/or be equally attenuated by early antiretroviral therapy initiation.",
keywords = "AIDS, HIV infection, immune activation, monocyte activation, non-AIDS events",
author = "Utay, {Netanya S.} and Hunt, {Peter W.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1097/COH.0000000000000242",
language = "English (US)",
volume = "11",
pages = "131--137",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Role of immune activation in progression to AIDS

AU - Utay, Netanya S.

AU - Hunt, Peter W.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose of review The purpose is to review recent insights into the impact of HIV-associated immune activation on AIDS and non-AIDS morbidity and mortality. Recent findings Immune activation has long been recognized as an important consequence of untreated HIV infection and predictor of AIDS progression, which declines but fails to normalize during suppressive antiretroviral therapy, and continues to predict disease in this setting. Thus, a major research agenda is to develop novel therapies to reduce persistent immune activation in treated HIV infection. Yet, the optimal targets for interventions remain unclear. Both the specific root causes of immune activation and the many interconnected pathways of immune activation that are most likely to drive disease risk in HIV-infected individuals remain incompletely characterized, but recent studies have shed new light on these topics. Summary In the context of this review, we will summarize recent evidence helping to elucidate the immunologic pathways that appear most strongly predictive of infectious and noninfectious morbidity. We will also highlight the likelihood that not all root drivers of immune activation - and the discrete immunologic pathways to which they give rise - are likely to produce the same disease manifestations and/or be equally attenuated by early antiretroviral therapy initiation.

AB - Purpose of review The purpose is to review recent insights into the impact of HIV-associated immune activation on AIDS and non-AIDS morbidity and mortality. Recent findings Immune activation has long been recognized as an important consequence of untreated HIV infection and predictor of AIDS progression, which declines but fails to normalize during suppressive antiretroviral therapy, and continues to predict disease in this setting. Thus, a major research agenda is to develop novel therapies to reduce persistent immune activation in treated HIV infection. Yet, the optimal targets for interventions remain unclear. Both the specific root causes of immune activation and the many interconnected pathways of immune activation that are most likely to drive disease risk in HIV-infected individuals remain incompletely characterized, but recent studies have shed new light on these topics. Summary In the context of this review, we will summarize recent evidence helping to elucidate the immunologic pathways that appear most strongly predictive of infectious and noninfectious morbidity. We will also highlight the likelihood that not all root drivers of immune activation - and the discrete immunologic pathways to which they give rise - are likely to produce the same disease manifestations and/or be equally attenuated by early antiretroviral therapy initiation.

KW - AIDS

KW - HIV infection

KW - immune activation

KW - monocyte activation

KW - non-AIDS events

UR - http://www.scopus.com/inward/record.url?scp=84957646468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957646468&partnerID=8YFLogxK

U2 - 10.1097/COH.0000000000000242

DO - 10.1097/COH.0000000000000242

M3 - Article

C2 - 26731430

AN - SCOPUS:84957646468

VL - 11

SP - 131

EP - 137

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 2

ER -